Shares of ImmuPharma plc (LON:IMM – Get Free Report) were down 8.5% on Monday . The stock traded as low as GBX 4.40 and last traded at GBX 4.40. Approximately 1,523,292 shares were traded during trading, a decline of 47% from the average daily volume of 2,874,877 shares. The stock had previously closed at GBX 4.81.
ImmuPharma Stock Down 8.5%
The firm’s 50 day simple moving average is GBX 4.48 and its two-hundred day simple moving average is GBX 5.83. The stock has a market cap of £27.45 million, a P/E ratio of -11.89 and a beta of 2.98.
ImmuPharma (LON:IMM – Get Free Report) last released its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
